Combination approaches of PD-1 and cytotoxic T lymphocyte-associated protein-4 inhibitors, which showed synergistic efficacy in melanoma [79], were associated with disappointing results in HNSCC [80]. This evidence concerns the gene CTLA4 and melanoma.